PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 10429660-5 1999 6,6"-Diester-trehaloses and 4,4"-diester-trehaloses of C8 to C12 fatty acids, 6,6"-diamide-trehaloses of C8 to C14 fatty acids, and n-dodecyl-beta-D-maltoside all inhibited TNF-alpha release in a dose-dependent manner. lauric acid 61-76 tumor necrosis factor Mus musculus 173-182 25811992-7 2015 We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells. lauric acid 21-24 tumor necrosis factor Mus musculus 121-148 25811992-7 2015 We demonstrated that ABL treatment significantly reduced neurological deficits and cerebral infarct volume by inhibiting tumor necrosis factor-alpha (TNF-alpha) and interleukin-1beta (IL-1beta) expression in ischemic cerebral tissue and OGD-treated BV2 cells. lauric acid 21-24 tumor necrosis factor Mus musculus 150-159 25811992-8 2015 Mechanistic studies suggested that the observed decrease in TNF-alpha and IL-1beta expression was attributable to the ABL-induced suppression of the expression of nuclear factor-kappa B (NF-kappaB) and Toll-like receptor 4 (TLR4). lauric acid 118-121 tumor necrosis factor Mus musculus 60-69 25811992-9 2015 We further found that miR-155 promoted TNF-alpha and IL-1beta expression by upregulating TLR4 and downregulating the expression of suppressor of cytokine signaling 1 (SOCS1) and myeloid differentiation primary response gene 88 (MyD88), while ABL exerted an inhibitory effect on miR-155-mediated gene expression. lauric acid 242-245 tumor necrosis factor Mus musculus 39-48